| Filed On | Filing |
|---|---|
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
On October 15, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available a presentation for investors. A copy of the presentation is attached hereto as Exhibit 99.1 and incorporated by r... |
| 22 Sep 2026 |
Form 3: Spiegel Robert J., Director
No securities owned |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 16 Sep 2026 |
8-K: Regulation FD Disclosure
On September 16, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available the corporate fact sheet and a presentation for investors. Copies of the corporate fact sheet and the presentat... |
| 01 Sep 2026 |
Form 4: Bristol James Arthur, Director
Granted 13,403 Stock Option (Right to buy) |
| 01 Sep 2026 |
Form 4: Cicala Peter, Director
Granted 11,026 Stock Option (Right to buy) |
| 01 Sep 2026 |
Form 4: Polinsky David, Director
Granted 5,083 Stock Option (Right to buy) |
| 01 Sep 2026 |
Form 4: Wexler William A., Director
Granted 5,943 Stock Option (Right to buy) |
| 01 Sep 2026 |
Form 4: Ratner Elena, Director
Granted 5,944 Stock Option (Right to buy) |
| 01 Sep 2026 |
Form 4: Luther Sanjeev, Director
Granted 118,848 Stock Option (right to buy) |
| 27 Aug 2026 |
Form 3: Polinsky David, Director
Holds 8,000 shares of Common Stock |
| 06 Aug 2026 | 10-Q |
| 02 Jul 2026 | 8-K: Regulation FD Disclosure |
| 02 Jul 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 26 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 20 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | SCHEDULE 13G |
| 14 May 2026 | SCHEDULE 13G |
Loading...
